ATAI Life Sciences AG’s $157 Million Series D Financing Round

Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced…

This content is for members only.
Login to Read More Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for members only.
Login to Read More Join Now